Navitas has acquired KAI Research to expand its trial site footprint in North America and Africa as well as bolster its ability to manage clinical trials in a number of research areas.
Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.
With almost 40% of attendees coming from outside the US, the political climate has had no effect on the latest CPhI franchise which starts today in Philadelphia.
Flamma has opened a new cGMP workshop and R&D Center in Dalian, China and is looking to add capacity at several other sites as part of its “Flamma 2020 plan.”
The Eagle is MHI’s Americanized version of its PF-D1S – a compact, servo-driven blister machine, and the company’s first entrance into the North American marketplace.
Parexel recently opened a new North American Coordination Hub and Distribution Center in Pennsylvania, which will provide customers with clinical trial supplies and logistics services.
WellSpring Pharma Services has announced a $3 million capital investment in new equipment in addition to a new strategic partnership with IDT Australia to manufacture drugs targeting the US market.
As competition and pricing get fiercer for CRO Charles River Laboratories, the company is looking to save about $35m from new efficiencies in its RMS (Research Models and Services) business, Jim Foster, chairman, president and CEO of CRL, told investors...
China-based WuXi PharmaTech has acquired CRO XenoBiotic Laboratories (XBL) to bolster its bioanalytical and DMPK (Drug Metabolism and Pharmacokinetics)/ADME (absorption, distribution, metabolism, and excretion) services. Financial terms were not disclosed....
Quintiles CEO Tom Pike told investors last week that the company is seeing “very strong demand from the larger pharmaceutical firms because their pipelines are full right now,” and at the same time, small biotech, with their plethora of funding, are starting...
Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets.
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
Pharmaceutical services provider UDG Healthcare (formerly United Drug) announced today the integration of its sales, marketing and medical service divisions into one group, named Ashfield.
Novo Nordisk's North American affiliate has a new President and more news from drug delivery firm Enteris - welcome to in-Pharmatechnologist.com' People on the Move.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
Pharma firms are returning to European and North American manufacturers as quality issues and rising costs have lost India and China some of its ‘Eastern promise,’ according to industry experts.
Preclinical CRO CiToxLAB has added inhalation testing capacity, citing growing demand from Pharmas and chemicals firms as key driver for the investment.
Australian preclinical services firm vivoPharma has opened a new vivarium and laboratory facility in the US as part of an effort to expand its global reach.
Canadian pharmaceutical packaging firm, Ropack, has begun stickpack production in its new state-of-the-art 15,000 sq. ft. dedicated manufacturing suite.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PPD, Clinilabs, Clearstone and Clariant.
Lab Research's main Canadian lender has obtained an order appointing receivers under section 243 of the bankruptcy and insolvency act after the firm's US private equity suitor lost interest in a takeover.
Albany Molecular Research Inc. (AMRI) has posted a fourth quarter loss for 2010 after charges relating to a non-cash goodwill and fixed asset impairment of $35.2m.
Oystar has sold its Brazilian unit, Oystar Fabrima, to Sao Paulo-headquartered firm Masipack in an effort to focus its business on country’s the primary and secondary packaging markets.
